To the MS Community:
It has been more than 20 months since Biogen Idec and Elan reintroduced TYSABRI® (natalizumab) in the U.S. and began launching in countries throughout the European Union, and we are pleased to see this therapy making an important impact on the lives of patients across the globe.
We responsibly reintroduced TYSABRI in the U.S. under one of the most comprehensive risk management plans in the industry – the TOUCH Prescribing Program – which is designed to facilitate the appropriate use of TYSABRI. Today, TYSABRI is approved in more than 30 countries, and most importantly, offers new hope to patients living with a serious, debilitating disease. Many patients have chosen to start TYSABRI therapy – as of the end of March 2008, approximately 26,000 patients were on commercial and clinical therapy worldwide.
Recent News About TYSABRI®